Botanical species · safety record

Dryopteris marginalis

The EFSA Compendium of Botanicals holds 6 constituent measurements for Dryopteris marginalis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Dryopteris marginalis (L.) A.Gray

6Constituent measurements

0Safety records

3Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Margaspidin	Roots and other underground parts	Solvent extraction	—	Gaschromatography (GC)	Resolve DOI
Phloroglucinol derivatives	Live plants	—	—	LC-MS	Resolve DOI
Margaspidin	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Phloroglucinol derivatives	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Phloroglucinol derivatives	Roots and other underground parts	Solvent extraction	≤ 2.58 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Phloroglucinol derivatives	Roots and other underground parts	Solvent extraction	≥ 0.95 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Penttil�, A., Kapadia, G.J. Isolation, structure, and synthesis of margaspidin, a new dryopteris phloroglucinol derivative. Journal of pharmaceutical sciences, 1965, vol. 54, no. 9, p. 1362-1364. DOI
WIDEN, CJ., BRITTON, DM. CHROMATOGRAPHIC AND CYTOLOGICAL STUDY OF DRYOPTERIS-FILIX-MAS AND RELATED TAXA IN NORTH-AMERICA . Canadian journal of botany, 1971, vol. 49, no. 9, p. 1589-&.
LOUNASMA.M., WIDEN, CJ., REICHSTE.T. MASS-SPECTRA OF NEW PHLOROGLUCIDES, ESPECIALLY THOSE WITH VALERYL SIDE CHAINS . Helvetica chimica acta, 1973, vol. 56, no. 3, p. 1133-1144. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature